All In Biotech

NDA 021887 · Haleon US Holdings

Alli

Orlistat · Oral · Intestinal Lipase Inhibitor

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Feb 7, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

65

3 Phase 3, 1 recruiting

FAERS reports

23,511

4,652 serious, 118 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 18, 2026.

Use for weight loss in overweight adults, 18 years and older, when used along with a reduced-calorie and low-fat diet

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 7, 2007 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
1 products under this application
  • ALLI · ORLISTAT 60MG · CAPSULE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Orlistat" as an intervention, any sponsor and status, largest first.

All 65 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,394
  • rectal discharge2,422
  • gastrointestinal disorder2,153
  • constipation1,916
  • diarrhoea1,825
  • weight increased1,821
  • flatulence1,589
  • steatorrhoea1,579
  • abdominal pain upper1,293
  • headache1,023
  • abdominal distension975
  • nausea835

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200429
200542
200631
20077,978
20085,952
2009602
2010493
2011290
2012177
2013122
20141,177
20151,801
2016669
2017673
2018660
2019577
2020497
2021428
2022201
2023340
2024315
2025260
2026197

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 434 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.